GLP1激动剂对生殖的影响
Marie Couldwell1, Anna Jane Tidwell2, Ann E Taylor3
1University of Utah Health, Division of Endocrinology, Salt Lake City, Utah.
The Journal of clinical endocrinology and metabolism
|July 14, 2025
概括
肥胖会损害男性和女性的生殖功能. 虽然减肥,有或没有GLP-1激动剂,可以提高生育能力,但这些药物对人类生殖健康的直接影响需要进一步研究.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 代谢性疾病研究研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖与男性和女性生殖功能障碍有关.
- 了解减肥的机制和确认减肥对生殖的好处一直是个挑战.
- 现有数据显示,体重减轻后生殖能力有所改善,有或没有类似葡萄糖-1 (GLP-1) 激动剂.
研究的目的:
- 审查GLP-1激动剂对人类生殖健康的影响的临床前和临床证据.
- 探索GLP-1激动剂在减肥之外对生殖器官的潜在直接益处.
- 提出治疗策略,并确定未来对肥胖相关生殖功能障碍的研究需求.
主要方法:
- 关于GLP-1激动剂对生殖途径的影响的临床前研究的综述.
- 对生殖功能和减肥干预措施的临床数据的分析.
- 综合证据来评估GLP-1激动剂的直接与体重介导作用.
主要成果:
- 临床前研究表明GLP-1激动剂可能直接影响下丘脑,生殖腺和子宫内膜.
- 减肥,与或没有GLP-1激动剂实现,一般改善生殖功能.
- GLP-1激动剂对人类生殖器官的直接影响,独立于减肥,仍然不确定.
结论:
- GLP-1激动剂在与肥胖相关的生殖功能障碍方面表现有前途,但由于潜在的胎儿毒性,需要谨慎.
- 进一步的研究是必不可少的,以澄清GLP-1激动剂对人类的直接生殖益处和安全性.
- 需要一种战略方法来平衡体重管理的好处与生殖健康方面的考虑.
相关概念视频
Glucagon-like Receptor Agonists
424
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
424
Dipeptidyl Peptidase 4 Inhibitors
262
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
262
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
267
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
267
Oral Hypoglycemic Agents: Glinides
268
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
268
Oral Hypoglycemic Agents: Biguanides and Glitazones
306
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
306
Hormones Regulating Blood Glucose
4.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.1K


